Isomorphic Labs, the AI drug design company led by Demis Hassabis, announced a $5 billion Series C on November 17, 2026. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz (a16z), several other new investors and continued investment from Alphabet. Hassabis put it on X in one line: “Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease.”
The announcement gives no valuation and names no drug in human trials. It says the company’s candidates have produced positive preclinical results and that the money takes them toward clinical trials. This page records what Isomorphic published on November 17, 2026.
On this page · 6 sectionsOpen
Isomorphic Labs announced a $5 billion Series C on November 17, 2026, co-led by Greenoaks and Sequoia Capital.
Andreessen Horowitz (a16z) and other new investors joined, Alphabet invested again, and every existing investor took part.
The money goes into IsoDDE, its drug design engine built from simulation AI models, and into models for new biology.
Isomorphic says its candidates have positive preclinical results and that the round takes them toward clinical trials.
Its internal programs are in oncology and immunology; the announcement gives no valuation and names no drug.
§ 01The round
| Role | Investors |
|---|---|
| Co-leads | Greenoaks and Sequoia Capital |
| New investors | Andreessen Horowitz (a16z) and several others |
| Investing again | Alphabet, with what the release calls continued significant investment |
| Existing investors, all of whom took part | Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund |
- The size. $5 billion, in a round the release calls oversubscribed.
- The reach. Hassabis’s post had about 431,000 views and Isomorphic’s own about 94,000 when we read them at 21:01 UTC.
- The company. Founded in 2021, headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland, led by Hassabis as CEO and Max Jaderberg as President.
§ 02What the money is for
| Area | What the release says |
|---|---|
| IsoDDE | Keep maturing its drug design engine, a suite of simulation models that work across therapeutic areas and drug modalities |
| New biology | Expand deeper into new biology with more advanced models |
| Pipeline | Advance internal programs in oncology and immunology, and programs with partners, toward clinical trials |
| Partners | Build a partner ecosystem to understand mechanistic disease biology |
| Infrastructure | Build translational and clinical development infrastructure, and global infrastructure for AI-led bioengineering |
Hassabis, in the release: “Our drug design engine is generating molecules with unprecedented precision and speed.” Jaderberg puts the pace in a sentence: “Every week we are making repeatable scientific advancements enabled by our models.”
§ 03IsoDDE, the engine behind the pitch
The release describes IsoDDE as a suite of foundational simulation AI models that explore large chemical spaces, and pairs it with proprietary agents that reason over complex biological systems. The claim is that the models push predictions towards experimental accuracy and turn into better molecules week after week. The investors frame it the same way. Greenoaks’ Neil Mehta: “Discovering and developing new medicines is an optimization challenge of almost infinite scale.” Sequoia’s Konstantine Buhler: “Using AI to improve human health is one of the most important challenges of our generation.”
§ 04What the announcement does not say
- No valuation. The release and the page give none.
- No named drug, and nothing in human trials yet. The programs have positive preclinical results, the release says, “setting the stage for clinical entry”.
- No partner names or deal terms. The release mentions work with partners without naming them.
Our reading, not Isomorphic’s: this is a very large private round for a company whose medicines have not yet reached a clinical trial. The release names the test itself: getting candidates designed with its models into human trials. Until that happens, the signals to watch are the first trial start and any named partner program.
§ 05Where CellCog sits
We build CellCog, a platform where a business hires AI employees, and those employees run on Anthropic’s Claude models. CellCog does not design drugs and has no tie to Isomorphic Labs or its investors. We cover the round as a record of AI doing scientific work; for how researchers use AI models day to day, see our earlier record.
§ 06Sources
- Isomorphic Labs, Series C announcement, read at 20:09 UTC on November 17, 2026
- The news release, dated London, 17 November 2026 (PDF), read at 20:51 UTC
- Demis Hassabis on X, 12:06 UTC, November 17, 2026
- Isomorphic Labs on X, 12:00 UTC, November 17, 2026
Q1How much did Isomorphic Labs raise?
Isomorphic Labs announced a $5 billion Series C on November 17, 2026, in a round co-led by Greenoaks and Sequoia Capital that the company calls oversubscribed.
Q2Who invested in Isomorphic Labs?
Greenoaks and Sequoia Capital led, with Andreessen Horowitz (a16z) and several other new investors, continued investment from Alphabet, and all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Q3What is IsoDDE?
Isomorphic’s drug design engine: a suite of simulation AI models that work across therapeutic areas and drug modalities, which the company uses with its own agents to design and refine molecules.
Q4Does Isomorphic Labs have drugs in clinical trials?
The announcement names none. It says internal programs in oncology and immunology, and programs with partners, have produced positive preclinical results, and that the round takes candidates toward clinical trials.
Q5What is Isomorphic Labs valued at?
The company did not give a valuation in its November 17, 2026 announcement.
